{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-086135","form_type":"8-K","ticker":"NTRA","cik":"0001604821","company_name":"Natera, Inc.","filed_at":"2022-08-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.338013+00:00","generated_at":"2026-06-24T04:09:30.995201+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Natera Q2 revenue up 40% to $198.2M; raises FY2022 guidance to $805M-$825M","bullets":["Total revenue $198.2M (+39.6% YoY); product revenue $194.6M (+39.3%).","Tests processed ~499,900, up 33% YoY; net loss $145.2M ($1.50/share) vs $116.0M ($1.32).","2022 revenue guidance raised to $805M-$825M; gross margin ~46%-48%.","Cash & investments $638.7M, down from $914.5M at Dec 31, 2021; net cash consumption expected $370M-$400M.","Selected for UnitedHealthcare Preferred Lab Network; Medicare coverage for Signatera in muscle invasive bladder cancer."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-086135","json":"https://secwatch.observer/filing/0001104659-22-086135.json","markdown":"https://secwatch.observer/filing/0001104659-22-086135.md","text":"https://secwatch.observer/filing/0001104659-22-086135.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1604821/000110465922086135/0001104659-22-086135-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1604821/000110465922086135/tm2222580d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T04:09:30.995201+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}